The Trump administration announced a new health guidance linking acetaminophen, known as Tylenol, use during pregnancy to autism, sparking an immediate debate among medical professionals about the health claim.
On Sept. 22, President Trump declared that pregnant women should avoid taking acetaminophen. He stated that the FDA will issue new physician notices and change safety labels on acetaminophen products. This followed evidence compiled by his administration, suggesting a possible association between prenatal acetaminophen use and increased autism risk in children. The announcement was made alongside Health Secretary Robert F. Kennedy Jr., fulfilling Kennedy’s earlier promise that “by September, we will know what has caused the autism epidemic, and we’ll be able to eliminate those exposures.”
Medical research presents an alternative perspective regarding acetaminophen and autism. A recent NIH-funded study by U.S. and Swedish scientists found no increased risk of autism from acetaminophen use during pregnancy. Groups like the Society for Maternal-Fetal Medicine continue recommending acetaminophen for treating fever and pain in pregnant women.
Students have expressed skepticism about the administration’s claims. “There shouldn’t be much of an issue to talk about here,” said senior Colin Merrell. “A majority of research studies on a possible link between acetaminophen and autism have found no link whatsoever, and many studies on this topic could have fairly large error ranges because Tylenol is taken over the counter.”
Research shows autism has strong genetic influences. Studies consistently demonstrate that environmental factors play a minimal role compared to genetics in autism development, challenging the claims that over-the-counter medications like acetaminophen serve as primary causes.
The Trump administration also recommended leucovorin, typically used in cancer treatment, as a possible autism therapy. The Autism Science Foundation states this research remains in early stages and requires more studies before reaching definitive conclusions.
“I think it is unprofessional to make claims that are not completely science-based,” said senior Vella Batdorf. “In the case of the president, if there isn’t clear scientific proof of anything, I don’t think he should be presenting it as a new discovery of information.”
Students and young adults encounter health information from various sources, including political announcements. Understanding how to evaluate scientific claims becomes crucial when different authorities present conflicting information.
“Lots of people with that political affiliation believe almost anything he says, and presenting information that may not be fully true could cause widespread misinformation,” Batdorf said. “The president is not a professional by any means on the information he is presenting.”
The announcement generated responses from medical professionals across the country. Healthcare organizations continue to provide evidence-based recommendations while combating Trump’s claim by addressing questions from patients about acetaminophen safety during pregnancy.
